683 Capital Management’s Lunai Bioworks LNAI Stock Holding History

683 Capital Management’s Portfolio LNAI Stock Details LNAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-921	Closed	-$234K	–	238
2023 Q4	$234K	Buy	+921	New	+$252K	0.02%	176
2022 Q2	–	Sell	-467	Closed	-$308K	–	319
2022 Q1	$308K	Hold	467	–	–	0.02%	232
2021 Q4	$272K	Buy	+467	New	+$339K	0.01%	269

Other funds holding LNAI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

683 Capital Management's LNAI Position: Q1 2024 in Review

683 Capital Management sold out of Lunai Bioworks (LNAI) in Q1 2024, closing a stake of 921 shares — an estimated $234K sold.

683 Capital Management first reported a position in LNAI in Q4 2021 and held it in 3 quarters. The position peaked at $308K in Q1 2022. 41 funds tracked by Wall St. Rank hold LNAI as of Q1 2024.

683 Capital Management reported no remaining Lunai Bioworks position as of Q1 2024 after selling out during the quarter.
683 Capital Management sold 921 Lunai Bioworks shares in Q1 2024, an estimated $234K.
683 Capital Management first reported a position in Lunai Bioworks in Q4 2021 and held it in 3 quarters.
683 Capital Management's Lunai Bioworks position peaked at $308K in Q1 2022.
41 funds tracked by Wall St. Rank held Lunai Bioworks as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.